title: High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
abstract: OBJECTIVE
  This study was carried out to examine P53-induced Ring-h2 protein (Pirh2) expression and investigate its clinical and prognostic significance in patients with clear cell renal cell carcinoma (ccRCC).
  
  
  METHODS
  Pirh2 mRNA and protein expressions were detected by quantitative reverse-transcription polymerase chain reaction (Q-RT PCR) and Western blotting in 35 frozen renal cancer tissue specimens and 35 adjacent normal renal tissue specimens of the same patients. Pirh2 protein expression was assessed by immunohistochemical analysis in 92 paraffin-embedded specimens of human ccRCC and 30 specimens of adjacent normal renal tissue. Correlations between Pirh2 and clinicopathologic features and prognosis were analyzed statistically.
  
  
  RESULTS
  Pirh2 mRNA and protein levels in ccRCC samples were increased significantly as compared with the adjacent normal renal tissues (P < 0.001). Pirh2 mRNA overexpression correlated with high stage and grade of the renal cancer (P < 0.001 and P < 0.001 respectively). Pirh2 protein expression was negative in most normal renal tissue specimens (23/30) but positive in 52.2% (48/92) of ccRCC specimens (P = 0.006). Pirh2 protein expression correlated with tumor grade and stage (P < 0.001 and P < 0.001 respectively). The median follow-up interval was 42.0 months. Overexpression of Pirh2 protein in ccRCC was significantly associated with shorter overall survival and recurrence-free survival (P = 0.001 and P = 0.003, respectively). Multivariate analysis showed that Pirh2 expression was an independent prognostic factor for ccRCC patients (P = 0.037).
  
  
  CONCLUSIONS
  Pirh2 was up-regulated in ccRCC at both transcriptional and translational levels compared with normal renal tissues, suggesting that Pirh2 may be a potential prognostic marker for ccRCC.
authors.affiliation: Department of Urology, Renji Hospital, Shanghai Jiaotong University, Shanghai 200001, China.
authors.forename: X R
authors.initials: XR
authors.lastname: Wu
authors.forename: J J
authors.initials: JJ
authors.lastname: Sha
authors.forename: D M
authors.initials: DM
authors.lastname: Liu
authors.forename: Y H
authors.initials: YH
authors.lastname: Chen
authors.forename: G L
authors.initials: GL
authors.lastname: Yang
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: Y Y
authors.initials: YY
authors.lastname: Chen
authors.forename: J J
authors.initials: JJ
authors.lastname: Bo
authors.forename: Y R
authors.initials: YR
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D015153:Blotting, Western; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000473:pathology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D044767:Ubiquitin-Protein Ligases / Q000032:analysis* / Q000235:genetics; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C485369:RCHY1 protein, human; D044767:Ubiquitin-Protein Ligases